在神经退行症中,白血信号传递:对治疗策略的影响
Veerta Sharma1, Prateek Sharma1, Thakur Gurjeet Singh2
1Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India.
Inflammopharmacology
|August 21, 2024
概括
胰岛素 (LTs),炎症分子,与阿尔茨海默氏症和帕金森症等神经退行性疾病有关. 针对LTs为这些中枢神经系统疾病提供了新的治疗策略.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
背景情况:
- 列科特里因 (LTs) 是通过5-氧酶 (5-LOX) 来从酸中获得的炎症调解剂.
- 乙烯LTs是过敏炎症的关键,并且在中枢神经系统 (CNS) 疾病中越来越被认可.
- LTs,5-LOX及其受体与神经退行性疾病有关,例如多发性硬化症 (MS),阿尔茨海默病 (AD) 和帕金森病 (PD).
研究的目的:
- 综合审查LTs的生物合成,受体和生物效应.
- 调查白血信号传递在中枢神经系统疾病和神经退行症中的作用和影响.
- 探索针对新型治疗干预措施的向白细胞三烯信号传导的潜力.
主要方法:
- 对当前的研究和实验进行了全面的文献综述.
- 分析了白血的生物合成途径.
- 检查leukotriene受体相互作用和生物效应.
主要成果:
- 莱科特里因信号传递与神经退行性疾病的炎症过程有关.
- 该研究详细介绍了LTs在中枢神经系统疾病中的复杂作用,包括MS,AD和PD.
- 药理上抑制白细胞三烯信号传递表明神经保护的前景.
结论:
- 莱科特里因信号传递在神经退行症中起着重要作用.
- 准白血蛋白通路为对抗神经退行性疾病提供了潜在的治疗途径.
- 选择性白血抑制剂代表了中枢神经系统疾病未来有前途的治疗方法.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
259
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
259
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:24Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
01:00Enzyme-linked Receptors
77.7K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.7K
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:15Parkinson's Disease: Overview
500
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
500